Lavone Smith, MD
Advanced Heart Failure and Transplant Cardiology · Richmond, VANPI 1710256094
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $14,250 of the $22,603 with a category attached, or 63.0%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 69.3% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $12,768 and has fallen 93.4% since, to $837 in 2025.
Across 306 payments — averaging $73.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$16K
- Abbott$3K
- Actelion Pharmaceuticals US, Inc.$1K
- Pfizer$568
- Novartis$328
- Cvrx, Inc.$308
- plus $2K from 15 others
What the payments were for
- Speaking & faculty fees$14,25063%
- Travel & lodging$3131%
- Food & beverage$7,75634%
- Education$2841%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 84 | $15,657 |
| Abbott | 79 | $2,971 |
| Actelion Pharmaceuticals US, Inc. | 48 | $1,031 |
| Pfizer | 25 | $568 |
| Novartis | 20 | $328 |
| Cvrx, Inc. | 5 | $308 |
| United Therapeutics Corporation | 9 | $256 |
| E.r. Squibb & Sons, L.L.C. | 4 | $255 |
| Impulse Dynamics (USA) Inc. | 3 | $217 |
| Boehringer Ingelheim | 6 | $192 |
| Alnylam Pharmaceuticals Inc. | 3 | $174 |
| AstraZeneca | 3 | $162 |
| Abiomed | 6 | $151 |
| Edwards Lifesciences | 2 | $143 |
| Bridgebio Pharma, Inc. | 2 | $44 |
| Atricure, Inc. | 1 | $33 |
| Inspire Medical Systems, Inc. | 1 | $29 |
| Sandoz | 2 | $29 |
| Bayer | 1 | $21 |
| Akcea Therapeutics, Inc. | 1 | $20 |
| Scpharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$14,250
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$582
- OPTIMIZER$301
- HeartMate 3 Left Ventricular Dev$277
- Barostim Neo System$222
- CAMZYOS$125
- WAINUA$122
- ONPATTRO$121
- VYNDAQEL$120
- CARDIOMEMS$118
- SAPIEN 3 Ultra RESILIA$107
- JARDIANCE$106
How this compares
$22,603 in reported general payments places this provider in the 75th percentile of 43 advanced heart failure and transplant cardiology providers in Virginia.
See all advanced heart failure and transplant cardiology providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 32 | $731,737 |
| EntrestoSacubitril/Valsartan | 126 | $117,667 |
| JardianceEmpagliflozin | 121 | $114,238 |
| FarxigaDapagliflozin Propanediol | 50 | $49,398 |
| Bumetanide | 86 | $2,271 |
| Hydralazine Hcl | 59 | $842 |
| Spironolactone | 166 | $752 |
| Potassium Chloride | 34 | $658 |
| Carvedilol | 83 | $632 |
| Rosuvastatin Calcium | 19 | $618 |
| Metoprolol Succinate | 49 | $452 |
| Allopurinol | 52 | $424 |
| Atorvastatin Calcium | 60 | $371 |
| Sildenafil Citrate | 12 | $329 |
| Torsemide | 21 | $295 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax | $568 | $731,73732 claims |
| NovartisEntresto | $328 | $117,667126 claims |
| Boehringer IngelheimJardiance | $192 | $114,238121 claims |
| AstraZenecaFarxiga | $162 | $49,39850 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 43 advanced heart failure and transplant cardiology providers in Virginia.
Other advanced heart failure and transplant cardiology in Richmond
- Edward SaweyRichmond$35K
- Neil LewisRichmond$9K
- Melissa SmallfieldRichmond$5K
- Pengyang LiRichmond$4K
- Inna TchoukinaRichmond$3K
- Nimesh PatelRichmond$2K
- Kelli FoxRichmond$2K
- Krishnasree RaoRichmond$605
- Anit MankadRichmond$425
- Sasa MitrovicRichmond$139
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.